drugset / Trial / NCT05844293
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
RandomizedSequentialDouble-blindTreatment
Summary
The purpose of this study is to evaluate safety, tolerability, PK, and PD of SAD of FXI-GalNAc-siRNA administered SC to healthy subjects.
Timeline
- Start
- 2023-05-16
- Primary completion
- 2024-05
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FXI-GalNAc-siRNA | Small interfering RNA (siRNA) | 25 mg | Subcutaneous |
| Subject | FXI-GalNAc-siRNA | Small interfering RNA (siRNA) | 50 mg | Subcutaneous |
| Subject | FXI-GalNAc-siRNA | Small interfering RNA (siRNA) | 100 mg | Subcutaneous |
| Subject | FXI-GalNAc-siRNA | Small interfering RNA (siRNA) | 200 mg | Subcutaneous |
| Subject | FXI-GalNAc-siRNA | Small interfering RNA (siRNA) | 400 mg | Subcutaneous |